This transcript is for your personal, non-commercial usage only. To bid presentation-ready copies for organisation to your colleagues, clients oregon customers sojourn http://www.djreprints.com.
https://www.barrons.com/articles/curevac-stock-mrna-covid-vaccine-51634041343
Updated Oct. 12, 2021 8:43 americium ET / Original Oct. 12, 2021 8:24 americium ET
- Order Reprints
- Print Article
CureVac banal fell 14.5% successful premarket trading.
Guillaume Souvant/AFP via Getty ImagesCureVac said aboriginal Tuesday it was halting improvement of its archetypal messenger RNA-based Covid-19 vaccine, and would alternatively absorption connected the RNA-based Covid-19 vaccine it is processing with GlaxoSmithKline.
Shares of CureVac (ticker: CVAC) dived 14.5% successful premarket trading.
The extremity of the roadworthy for the archetypal CureVac mRNA vaccine, which it calls CVnCoV,...
English (US) ·